PT1320534E - Sais de pro-farmacos de fosfato de combretastatina a-4 com compostos azotados - Google Patents
Sais de pro-farmacos de fosfato de combretastatina a-4 com compostos azotadosInfo
- Publication number
- PT1320534E PT1320534E PT01970806T PT01970806T PT1320534E PT 1320534 E PT1320534 E PT 1320534E PT 01970806 T PT01970806 T PT 01970806T PT 01970806 T PT01970806 T PT 01970806T PT 1320534 E PT1320534 E PT 1320534E
- Authority
- PT
- Portugal
- Prior art keywords
- combretastatin
- pharmacology
- pro
- phosphate
- hybrid compounds
- Prior art date
Links
- WDOGQTQEKVLZIJ-WAYWQWQTSA-N combretastatin a-4 phosphate Chemical compound C1=C(OP(O)(O)=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 WDOGQTQEKVLZIJ-WAYWQWQTSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/14—Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/12—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23256800P | 2000-09-14 | 2000-09-14 | |
| US25192100P | 2000-12-07 | 2000-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1320534E true PT1320534E (pt) | 2005-08-31 |
Family
ID=26926130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT01970806T PT1320534E (pt) | 2000-09-14 | 2001-09-12 | Sais de pro-farmacos de fosfato de combretastatina a-4 com compostos azotados |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US6670344B2 (pt) |
| EP (1) | EP1320534B1 (pt) |
| JP (2) | JP4149804B2 (pt) |
| KR (1) | KR100858464B1 (pt) |
| CN (1) | CN100338077C (pt) |
| AR (1) | AR030727A1 (pt) |
| AT (1) | ATE293630T1 (pt) |
| AU (2) | AU785183B2 (pt) |
| BR (1) | BRPI0107210B1 (pt) |
| CA (1) | CA2422359C (pt) |
| DE (1) | DE60110249T2 (pt) |
| EE (1) | EE200200249A (pt) |
| ES (1) | ES2241872T3 (pt) |
| HK (1) | HK1052356B (pt) |
| HU (1) | HU229055B1 (pt) |
| IL (3) | IL149601A0 (pt) |
| MX (1) | MXPA03002209A (pt) |
| NO (1) | NO329973B1 (pt) |
| NZ (1) | NZ524926A (pt) |
| PE (1) | PE20020445A1 (pt) |
| PT (1) | PT1320534E (pt) |
| RS (1) | RS50309B (pt) |
| SK (1) | SK287117B6 (pt) |
| TW (1) | TWI250163B (pt) |
| UY (1) | UY26935A1 (pt) |
| WO (1) | WO2002022626A1 (pt) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0019944D0 (en) * | 2000-08-15 | 2000-09-27 | Angiogene Pharm Ltd | Compositions with vascular damaging activity |
| US20050153939A1 (en) * | 2003-09-10 | 2005-07-14 | Bristol-Myers Squibb Company | Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts |
| US6670344B2 (en) * | 2000-09-14 | 2003-12-30 | Bristol-Myers Squibb Company | Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts |
| US7603190B2 (en) * | 2001-04-19 | 2009-10-13 | Sony Corporation | Digital recording/reproducing apparatus |
| EP1406600A4 (en) * | 2001-07-13 | 2007-06-06 | Oxigene Inc | COMPOSITIONS AND METHOD FOR THE ADMINISTRATION OF TUBULIN BINDING AGENTS FOR THE TREATMENT OF EYE DISEASES |
| US20040229960A1 (en) * | 2001-07-13 | 2004-11-18 | David Sherris | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| US20090137687A1 (en) * | 2003-02-28 | 2009-05-28 | Oxigene, Inc. | Compositions and Methods With Enhanced Therapeutic Activity |
| CN100365000C (zh) * | 2003-09-18 | 2008-01-30 | 雍智全 | Combretastatin A-4磷酰胆碱类前体药物以及其合成与应用 |
| EP1696934B1 (en) | 2003-12-23 | 2013-05-29 | Schering-Plough Ltd. | Florfenicol prodrug having improved water solubility |
| TW200534879A (en) * | 2004-03-25 | 2005-11-01 | Bristol Myers Squibb Co | Coated tablet formulation and method |
| US7829720B2 (en) | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
| US20050256314A1 (en) * | 2004-05-04 | 2005-11-17 | Soojin Kim | Process employing controlled crystallization in forming crystals of a pharmaceutical |
| TWI415635B (zh) * | 2004-05-28 | 2013-11-21 | 必治妥施貴寶公司 | 加衣錠片調製物及製備彼之方法 |
| WO2006138427A2 (en) | 2005-06-14 | 2006-12-28 | Baylor University | Combretastatin analogs with tubulin binding activity |
| CN1907989B (zh) * | 2005-08-02 | 2011-08-17 | 浙江天皇药业有限公司 | 毛兰素盐及其制备方法和包含其的药物组合物 |
| BRPI0620040A2 (pt) * | 2005-12-19 | 2011-10-25 | Methylgene Inc | inibidores de histona desacetilase para realçar a atividade de agentes antifúngicos |
| JP5844028B2 (ja) | 2006-04-04 | 2016-01-13 | ケージー アクキュイシチオン エルエルシー | 抗血小板薬及び酸阻害薬を含む経口剤形 |
| WO2008001204A2 (en) * | 2006-06-29 | 2008-01-03 | Antares Pharma Ipl Ag | Transdermal compositions of pramipexole having enhanced permeation properties |
| KR20090094383A (ko) | 2006-12-19 | 2009-09-04 | 메틸진 인크. | 히스톤 탈아세틸화효소의 억제제 및 이의 프로드럭 |
| US8796330B2 (en) * | 2006-12-19 | 2014-08-05 | Methylgene Inc. | Inhibitors of histone deacetylase and prodrugs thereof |
| US20090012325A1 (en) * | 2007-02-22 | 2009-01-08 | Ajith Manage | Methods for preparing phosphoric acids of combrestastatin and derivatives thereof |
| US20080214509A1 (en) * | 2007-03-02 | 2008-09-04 | Robert Kerbel | Methods for enhancing the efficacy of vascular disrupting agents |
| SI2178513T1 (sl) * | 2007-06-22 | 2011-05-31 | Bristol Myers Squibb Co | Tabletni sestavki vsebujoäśi atazanavir |
| PT2170292E (pt) * | 2007-06-22 | 2014-03-06 | Bristol Myers Squibb Holdings Ireland | Composições de comprimido contendo atazanavir |
| DE602008005316D1 (de) * | 2007-06-22 | 2011-04-14 | Bristol Myers Squibb Co | Tablettierte atazanavirhaltige zusammensetzungen |
| EP2178512B1 (en) * | 2007-06-22 | 2011-03-09 | Bristol-Myers Squibb Company | Tableted compositions containing atazanavir |
| US20090264382A1 (en) | 2007-11-21 | 2009-10-22 | David Chaplin | Methods for Treating Hematopoietic Neoplasms |
| CN102757338B (zh) * | 2012-02-29 | 2015-02-25 | 郑州泰基鸿诺药物科技有限公司 | 一种非诺贝特酸氨基酸乙酯盐、制备方法及其用途 |
| US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
| EP2972394A4 (en) | 2013-03-15 | 2016-11-02 | Sloan Kettering Inst Cancer | HSP90 TARGETING CARDIAC IMAGING AND TREATMENT THEREOF |
| US11419934B2 (en) | 2015-08-18 | 2022-08-23 | Oncotelic Therapeutics, Inc. | Use of VDAS to enhance immunomodulating therapies against tumors |
| WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| US12030888B2 (en) | 2021-02-24 | 2024-07-09 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5231112A (en) | 1984-04-12 | 1993-07-27 | The Liposome Company, Inc. | Compositions containing tris salt of cholesterol hemisuccinate and antifungal |
| DE3438386A1 (de) | 1984-09-22 | 1986-04-03 | Basf Ag, 6700 Ludwigshafen | Phosphorsaeurevinylbenzylester, ihre herstellung und verwendung |
| GB9106177D0 (en) | 1991-03-22 | 1991-05-08 | Aston Molecules Ltd | Substituted diphenylethylenes and analogues or derivatives thereof |
| US5561122A (en) * | 1994-12-22 | 1996-10-01 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Combretastatin A-4 prodrug |
| DE19506885A1 (de) | 1995-02-17 | 1996-08-22 | Schering Ag | Neue Borneolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
| TW334418B (en) | 1995-03-07 | 1998-06-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions |
| WO1999035159A1 (en) * | 1998-01-08 | 1999-07-15 | Brigham & Women's Hospital, Inc. | Lymphoma/leukemia oncogene, oncoprotein and methods of use |
| CA2314238C (en) * | 1998-01-09 | 2008-09-02 | Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University | Synthesis of combretastatin a-4 prodrugs and trans-isomers thereof |
| GB9903404D0 (en) | 1999-02-16 | 1999-04-07 | Angiogene Pharm Ltd | Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis |
| GB9903403D0 (en) | 1999-02-16 | 1999-04-07 | Angiogene Pharm Ltd | Substituted stilbene compounds with vascular damaging activity |
| GB0019944D0 (en) | 2000-08-15 | 2000-09-27 | Angiogene Pharm Ltd | Compositions with vascular damaging activity |
| US6670344B2 (en) * | 2000-09-14 | 2003-12-30 | Bristol-Myers Squibb Company | Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts |
-
2001
- 2001-09-11 US US09/950,500 patent/US6670344B2/en not_active Expired - Lifetime
- 2001-09-12 TW TW090122636A patent/TWI250163B/zh not_active IP Right Cessation
- 2001-09-12 JP JP2002526877A patent/JP4149804B2/ja not_active Expired - Fee Related
- 2001-09-12 HU HU0204423A patent/HU229055B1/hu not_active IP Right Cessation
- 2001-09-12 CA CA002422359A patent/CA2422359C/en not_active Expired - Fee Related
- 2001-09-12 WO PCT/US2001/028401 patent/WO2002022626A1/en active Application Filing
- 2001-09-12 AT AT01970806T patent/ATE293630T1/de active
- 2001-09-12 DE DE60110249T patent/DE60110249T2/de not_active Expired - Lifetime
- 2001-09-12 EP EP01970806A patent/EP1320534B1/en not_active Expired - Lifetime
- 2001-09-12 AU AU90771/01A patent/AU785183B2/en not_active Ceased
- 2001-09-12 IL IL14960101A patent/IL149601A0/xx active IP Right Grant
- 2001-09-12 KR KR1020027006168A patent/KR100858464B1/ko active IP Right Grant
- 2001-09-12 RS YUP-348/02A patent/RS50309B/sr unknown
- 2001-09-12 ES ES01970806T patent/ES2241872T3/es not_active Expired - Lifetime
- 2001-09-12 SK SK672-2002A patent/SK287117B6/sk not_active IP Right Cessation
- 2001-09-12 EE EEP200200249A patent/EE200200249A/xx unknown
- 2001-09-12 CN CNB018031404A patent/CN100338077C/zh not_active Expired - Fee Related
- 2001-09-12 NZ NZ524926A patent/NZ524926A/en not_active IP Right Cessation
- 2001-09-12 MX MXPA03002209A patent/MXPA03002209A/es active IP Right Grant
- 2001-09-12 PT PT01970806T patent/PT1320534E/pt unknown
- 2001-09-12 BR BRPI0107210-2A patent/BRPI0107210B1/pt not_active IP Right Cessation
- 2001-09-13 UY UY26935A patent/UY26935A1/es not_active Application Discontinuation
- 2001-09-13 AR ARP010104346A patent/AR030727A1/es unknown
- 2001-09-14 PE PE2001000927A patent/PE20020445A1/es not_active Application Discontinuation
-
2002
- 2002-05-12 IL IL149601A patent/IL149601A/en unknown
- 2002-05-13 NO NO20022270A patent/NO329973B1/no not_active IP Right Cessation
-
2003
- 2003-06-27 HK HK03104615.4A patent/HK1052356B/zh not_active IP Right Cessation
- 2003-09-10 US US10/660,439 patent/US6855702B2/en not_active Expired - Lifetime
-
2006
- 2006-06-04 IL IL176088A patent/IL176088A0/en unknown
-
2007
- 2007-01-19 AU AU2007200218A patent/AU2007200218A1/en not_active Abandoned
-
2008
- 2008-05-07 JP JP2008121719A patent/JP2008195740A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1320534E (pt) | Sais de pro-farmacos de fosfato de combretastatina a-4 com compostos azotados | |
| EE200200669A (et) | Uued triasolopürimidiini ühendid | |
| EE200100483A (et) | Põletikuvastaste vahenditena kasutatavad ühendid | |
| NO20032585D0 (no) | ABCA-1 forhöyende forbindelser | |
| NO20026196L (no) | Kinazolinditosylatsalt-forbindelser | |
| DK1619192T3 (da) | Arylkondeserede azapolycykliske forbindelser | |
| DE60135235D1 (de) | Phenolharzzusammensetzung | |
| PT1250321E (pt) | Composicao de gliburida | |
| AR028410A1 (es) | Fabricacion de baterias | |
| DE60140787D1 (de) | ion | |
| DE60037755D1 (de) | Härtbare zusammensetzung | |
| ID29793A (id) | Komposisi bahan pelumas | |
| PT1086097E (pt) | Compostos sulfonilbenzeno como agentes anti-inflamatorios/analgesicos | |
| DE60019572D1 (de) | Resorcinderivate | |
| DE60116858D1 (de) | Zusammensetzung | |
| ATE372338T1 (de) | Deshalogenverbindungen | |
| NO20030303L (no) | Kalsilytiske forbindelser | |
| AR028218A1 (es) | Composicion endoparasiticidas | |
| EE200100489A (et) | Resortsinooli kompositsioon | |
| NO20023508D0 (no) | Kalsilyttiske forbindelser | |
| NO20031837D0 (no) | Kalsilytiske forbindelser | |
| TR200100070A3 (tr) | Bilesim | |
| FR2805337B1 (fr) | Reserve de rafraichissement | |
| BR0112787B1 (pt) | composiÇço de soluÇço topicamente administrÁvel. | |
| PT1318800E (pt) | 1-aminoalquilciclo-hexanos como agentes tripanocidas |